Synopsis:-Veerhealth Care Limited has disclosed receipt of its single largest-ever order worth Rs. 6.16 crore from an unnamed leading FMCG company in the personal and household care segment for the supply of face care products, to be executed within 45 days.
A Mumbai-registered micro-cap Ayurvedic and personal care manufacturer came into focus on Monday after filing a press release with BSE disclosing the single largest order in its operating history.
With a market capitalisation of Rs. 40.64 crore, the shares of Veerhealth Care Limited were last trading at Rs. 20.32 per share, up 1.70 from its previous close of Rs.19.98. It is trading at a P/E of 50.80
The Rs. 6.16 crore order covers the supply of face care products and has been placed by a leading FMCG company operating in the domestic and international personal and household care segment, described in the filing as belonging to a 125-year-old business group. The company has not disclosed the buyer’s name. Execution is expected within 45 days. The filing describes this as the company’s largest single order received to date.
To contextualise the order’s size: Veerhealth Care reported revenue from operations of approximately Rs. 7.26 crore in Q3 FY26 per Screener.in data. The Rs. 6.16 crore order represents approximately 85 percent of a single quarter’s revenue, and the company estimates it at roughly 20 percent of its full-year FY26 revenue expectation. Both figures speak to the order’s materiality relative to the company’s current operating scale.
The filing also notes that the buyer operates in export markets alongside domestic markets. Relevant because Veerhealth Care positions its USFDA plant clearance as a key differentiator. Very few micro-cap manufacturers in the Ayurvedic and personal care space carry USFDA approval, and if the current order signals a deepening relationship with a large FMCG client who sources for both domestic and international channels, that is a genuine.
Management has guided for FY27 total revenues of Rs. 50 to 60 crore with a PAT margin of 7 to 10 percent, with commentary that discussions with domestic and export buyers may push revenues above that range. The company has also stated an expectation of reaching Rs. 100 crore in revenues with 10 percent PAT within the next 18 months.
These projections warrant careful scrutiny. Veerhealth Care’s annualised revenue run rate is approximately Rs. 21 crore. Reaching Rs. 50 to 60 crore in FY27 would require more than doubling that run rate in a single year; reaching Rs. 100 crore within 18 months would require nearly a fivefold increase from current levels. The order pipeline may be growing, but these are aspirational figures that should be treated as management’s stated ambition rather than conservative guidance.
The financial profile at Veerhealth Care carries several structural flags. ROCE stands at 3.14 percent and three-year average ROE at 3.88 percent, both well below the cost of capital for any business, and a signal that the returns generated on deployed capital have not historically been meaningful. Quarterly operating margins have been sharply volatile, ranging from negative to 17 percent across recent periods, reflecting the lumpy, order-driven nature of the revenue model.
The most significant governance concern is promoter shareholding. At 31.5 percent, the promoter stake is already low for a micro-cap company, and it has declined by 12.9 percentage points over the past three years. Promoter stake erosion at this scale in a company of this size deserves a clear explanation Rs. whether through regulatory disclosures, pledging data, or direct management commentary Rs. before retail investors assign a premium valuation to the order win narrative.
Business Overview
Veerhealth Care Limited, incorporated in 1992, is a BSE-listed manufacturer of Ayurvedic medicines, oral care, and personal care products, operating under the AyuVeer brand. The company’s manufacturing facility is located in Vapi, Gujarat, and carries USFDA plant clearance. Its service offering includes contract manufacturing, white labelling, product development, and custom formulation for FMCG clients.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Veerhealth Care Stock In Focus After Bagging ₹6.16 Cr Order appeared first on Trade Brains.